Stay updated with breaking news from Petera Merkel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Throughout 2023, interest in the application of CAR-T and other cell therapies to autoimmune disease skyrocketed, with a multitude of clinical trials being initiated by various companies.
Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab (Nucala) in a head-to-head phase 3 trial of the two drugs.
/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for...
/PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced...
New York, NY (PRWEB) March 15, 2022 -- The National Institutes of Health (NIH) Clinical Center held its annual event, Rare Disease Day at the NIH, on February